Scholar Rock Holding Corporatio
SRRK
Positions held
Your positionsSRRK isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Scholar Rock is positioned in the biotechnology sector, which is known for its potential high growth due to continuous innovation and demand for new therapies.
- The company has a market cap of approximately $5.17 billion, indicating significant investor interest and potential for future growth.
- Despite current challenges, Scholar Rock has a strong buy recommendation with a target mean price of $70.44.
- The company has consistently reported zero revenue, which raises concerns about its ability to sustain operations and attract further investment.
- Scholar Rock's net income has been negative for several quarters, with a net loss of $109.90 million in Q2 2026.
- The stock has a strong sell signal with a score of -16.00, indicating bearish market sentiment and potential ongoing financial difficulties.
Fundamentals
| Market cap | $5.14B | Enterprise value | $4.85B | Trailing P/E | — | Forward P/E | -16.72 |
| PEG | — | Price / book | 20.22 | Beta | 0.62 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -1.7% | ROA | -58.8% | Debt / equity | 0.80 |
| Current ratio | 7.02 | Free cash flow | -$153.88M | Analyst recommendation | strong_buy | Mean target | $70.44 |
| 52w high | $61.76 | 52w low | $27.07 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$110M | -$106M | -$91.0M | -$102M | -$110M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$109M | -$102M | -$91.9M | -$104M | -$112M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $33.2M |
| Op margin | — | — | — | -404.8% |
| Net income | -$378M | -$246M | -$166M | -$135M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$385M | -$252M | -$171M | -$134M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Scholar Rock Resubmits Apitegromab Application in EU for Spinal Muscular Atrophy
2026-10-02 · 3 drug targets pharma is betting on next
2026-09-28 · FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals
2026-09-25 · Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says
2026-09-24 · Truist Lifts Price Target on Scholar Rock Holding to $77 From $76, Keeps Buy Rating
2026-09-21 · Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-18 · This week in charts: GSK’s China deals, the $300M IPO club and selling the news
2026-09-17 · Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?
2026-09-15 · Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions
2026-09-15 · Scholar Rock Shares Fall After Barclays Downgrade
2026-09-15 · Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says
Price (daily)
Full chart · RSI · MACD · patterns